Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CYP and transporter probe substrates · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single sequence, 3-period DDI (drug-drug interaction) | EXPERIMENTAL | Single sequence |
| Name | Type | Description |
|---|---|---|
| CYP and transporter probe substrates | DRUG | Cocktail of CYP (cytochrome P450) and transporter probe substrates |
| BMS-955176 | DRUG | BMS-955176 |
| BMS-955176 plus CYP and transporter probe substrates | DRUG | BMS-955176 plus the cocktail of CYP and transporter probe substrates |
Inclusion Criteria: 1. Written Informed Consent 2. Healthy male and female (not of childbearing potential) subjects as determined by medical history, surgical history, physical examination, vital signs, ECGs, and clinical laboratory determinations 3. Body mass index (BMI) of 18.0 kg/m2 to 32.0 kg/m...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
CYP and transporter probe substrates are investigational small molecules being studied for use in HIV Infections. They are currently in Phase 1 clinical development, with one completed trial involving 59 participants. The drug is not approved and remains under investigation for this indication.
CYP and transporter probe substrates are designed to interact with cytochrome P450 (CYP) enzymes and drug transporters. These targets are involved in drug metabolism and disposition, and the drug is being studied to understand its effects on the pharmacokinetics of other medications in the context of HIV treatment.
CYP and transporter probe substrates is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research on this investigational drug for the treatment of HIV Infections.
CYP and transporter probe substrates is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is still in the early stages of clinical testing, with one Phase 1 trial completed to date.
CYP and transporter probe substrates has one completed clinical trial, NCT02578277, titled 'Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates'. This Phase 1 study enrolled 59 participants with HIV Infections in the United States and included healthy volunteers.